Eftilagimod Alfa

4 trials

Filter these 4 trials by condition, phase, country and more.

Open in Search →

4 Registered trials

0 Recruiting

4 Completed trials

2 Sponsors

16 Countries

Phase III

Phase II/III

Phase II

Phase III: 1 Phase II/III: 1 Phase II: 2

Oversight events:

1 urgent safety measure across 1 trial

View oversight register →

Indications tested

Breast cancer stage IV 1 Non-small cell lung cancer metastatic 1 Head and neck cancer metastatic 1

Sponsors using this IMP

Immutep 3 Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy 1

All trials

4 total

Study to test new drug eftilagimod alfa (also known as efti) combined with standard marketed treatments (pembrolizumab and chemotherapy) in … Ended

2024-513621-23-00 Phase III 15 countries Immutep
Phase II study evaluating the efficacy and safety of preoperative immunotherapy (pembrolizumab with eftilagimod alfa) in combination with ra… Ended

2024-515971-37-00 Phase II 1 country Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Panstwowy Instytut Bada…
A study in metastatic breast cancer patients receiving eftilagimod alpha or placebo in combination with a standard chemotherapy (paclitaxel) Ended

2024-511023-34-00 Phase II/III 2 countries Immutep
Phase II Study of efti plus pembrolizumab combination therapy for head and neck cancer (HNSCC). Ended

2024-510762-16-00 Phase II 5 countries Immutep

Showing 1–4 of 4 trials

← All drugs A–Z